Minimal Hepatic Encephalopathy (MHE), A burden or an opportunity to ease one: A review
Keywords:
Minimal hepatic encephalopathy, Diagnostic tools/PrinciplesAbstract
A brain dysfunction caused by liver insufficiency is Hepatic Encephalopathy (HE). It has a spectrum of progression with varying and wide clinical and subclinical abnormalities. This review article will particularly focus on covert stages of HE i.e. A mildest and reversible neuropsychological complication with wide ranging manifestations throughout the spectrum of disease progression. By forming a correlation between varying clinical and sub-clinical symptoms with an awareness towards pathophysiological factors involved, a potent future approach could be established. However, lack of studies to establish such relationships makes it a laborious task keeping the non-specific symptoms of HE in site. But, with present severity and number progression, it is established by the use varying diagnostic tools, up to 80% of persons suffering through liver disease developed Minimal Hepatic Encephalopathy (MHE) as a further complication, making further research even crucial as so in order to avail better QoL (Quality of Life), socioeconomic status to subjects. The heterogeneous nature requires the testing of different diagnostic tools with a personalized analysis in order to form an effective treatment protocol. This article will focus on critical evaluation of different diagnostic techniques and treatments available with a view to cure MHE and keeping an open end point as to favour varying case by case basis approach and to prevent the further progression into its overt stages.
References
Cao, Q., Yu, C. B., Yang, S. G., Cao, H. C., Chen, P., Deng, M., & Li, L. J. (2018). Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A metaanalysis. Hepatobiliary & pancreatic diseases international: HBPD INT, 17(1), 9–16. https://doi.org/10.1016/j.hbpd.2018.01.005.
Cauli, O., Rodrigo, R., Piedrafita, B., Boix, J., & Felipo, V. (2007). Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology (Baltimore, Md.), 46(2), 514–519. https://doi.org/10.1002/hep.21734
Cheon, S. Y., & Song, J. (2021). The Association between Hepatic Encephalopathy and Diabetic Encephalopathy: The Brain-Liver Axis. International journal of molecular sciences, 22(1), 463. https://doi.org/10.3390/ijms22010463
Coltart, I., Tranah, T. H., & Shawcross, D. L. (2013). Inflammation and hepatic encephalopathy. Archives of biochemistry and biophysics, 536(2), 189–196. https://doi.org/10.1016/j.abb.2013.03.016.
Dalal, R., McGee, R. G., Riordan, S. M., & Webster, A. C. (2017). Probiotics for people with hepatic encephalopathy. The Cochrane database of systematic reviews, 2(2), CD008716. https://doi.org/10.1002/14651858.CD008716.pub3.
Dhiman, R. K., Saraswat, V. A., Sharma, B. K., Sarin, S. K., Chawla, Y. K., Butterworth, R., Duseja, A., Aggarwal, R., Amarapurkar, D., Sharma, P., Madan, K., Shah, S., Seth, A. K., Gupta, R. K., Koshy, A., Rai, R. R., Dilawari, J. B., Mishra, S. P., Acharya, S. K., & Indian National Association for Study of the Liver (2010). Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. Journal of gastroenterology and hepatology, 25(6), 1029–1041. https://doi.org/10.1111/j.1440-1746.2010.06318.x
Fogel, W. A., Andrzejewski, W., & Maśliński, C. (1990). Neurotransmitters in hepatic encephalopathy. Acta neurobiologiae experimentalis, 50(4-5), 281–293.
Goh, E. T., Stokes, C. S., Sidhu, S. S., Vilstrup, H., Gluud, L. L., & Morgan, M. Y. (2018). L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. The Cochrane database of systematic reviews, 5(5), CD012410. https://doi.org/10.1002/14651858.CD012410.pub2
Guerit, J. M., Amantini, A., Fischer, C., Kaplan, P. W., Mecarelli, O., Schnitzler, A., Ubiali, E.,
Amodio, P., & members of the ISHEN commission on Neurophysiological Investigations (2009). Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver international : official journal of the International Association for the Study of the Liver, 29(6), 789–796. https://doi.org/10.1111/j.1478-3231.2009.02030.x.
Häberle J. (2011). Clinical practice: the management of hyperammonemia. European journal of pediatrics, 170(1), 21–34. https://doi.org/10.1007/s00431-010-1369-2Kristiansen R. G. (2016). Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure. Metabolic brain disease, 31(6), 1357–1358. https://doi.org/10.1007/s11011-016-9908-9.
